Table of Contents Author Guidelines Submit a Manuscript
Advances in Medicine
Volume 2014, Article ID 473134, 17 pages
http://dx.doi.org/10.1155/2014/473134
Review Article

Mesenchymal Conversion of Mesothelial Cells Is a Key Event in the Pathophysiology of the Peritoneum during Peritoneal Dialysis

Centro de Biología Molecular-Severo Ochoa, CSIC, UAM, Cantoblanco, C/Nicolás Cabrera 1, 28049 Madrid, Spain

Received 12 August 2013; Revised 9 November 2013; Accepted 18 November 2013; Published 23 January 2014

Academic Editor: Anjali Satoskar

Copyright © 2014 Manuel López-Cabrera. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Chaimovitz, “Peritoneal dialysis,” Kidney International, vol. 45, no. 4, pp. 1226–1240, 1994. View at Google Scholar · View at Scopus
  2. O. Devuyst, P. J. Margetts, and N. Topley, “The pathophysiology of the peritoneal membrane,” Journal of the American Society of Nephrology, vol. 21, no. 7, pp. 1077–1085, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. R. T. Krediet, “The peritoneal membrane in chronic peritoneal dialysis,” Kidney International, vol. 55, no. 1, pp. 341–356, 1999. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Breborowicz and D. G. Oreopoulos, “Biocompatibility of peritoneal dialysis solutions,” American Journal of Kidney Diseases, vol. 27, no. 5, pp. 738–743, 1996. View at Google Scholar · View at Scopus
  5. K. Wieczorowska-Tobis, A. Polubinska, J. Wisniewska et al., “Multidirectional approach to study peritoneal dialysis fluid biocompatibility in a chronic peritoneal dialysis model in the rat,” Nephrology Dialysis Transplantation, vol. 16, no. 3, pp. 655–656, 2001. View at Google Scholar · View at Scopus
  6. K. Wieczorowska-Tobis, A. Styszynski, A. Breborowicz, and D. G. Oreopoulos, “Comparison of the biocompatibility of phosphate-buffered saline alone, phosphate-buffered saline supplemented with glucose, and dianeal 3.86%,” Peritoneal Dialysis International, vol. 21, supplement 3, pp. S362–S364, 2001. View at Google Scholar · View at Scopus
  7. M. Krishnan, P. Tam, G. Wu, A. Breborowicz, and D. G. Oreopoulos, “Glucose degradation products (GDP's) and peritoneal changes in patients on chronic peritoneal dialysis: will new dialysis solutions prevent these changes?” International Urology and Nephrology, vol. 37, no. 2, pp. 409–418, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. C. J. Holmes, “Biocompatibility of peritoneal dialysis solutions,” Peritoneal Dialysis International, vol. 13, no. 2, pp. 88–94, 1993. View at Google Scholar · View at Scopus
  9. C. J. Holmes and D. Faict, “Peritoneal dialysis solution biocompatibility: definitions and evaluation strategies,” Kidney International, vol. 64, no. 88, pp. S50–S56, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. L. A. Cooker, P. Luneburg, C. J. Holmes et al., “Interleukin-6 levels decrease in effluent from patients dialyzed with bicarbonate/lactate-based peritoneal dialysis solutions,” Peritoneal Dialysis International, vol. 21, supplement 3, pp. S102–S107, 2001. View at Google Scholar · View at Scopus
  11. R. Mackenzie, C. J. Holmes, S. Jones, J. D. Williams, and N. Topley, “Clinical indices of in vivo biocompatibility: the role of ex vivo cell function studies and effluent markers in peritoneal dialysis patients,” Kidney International, vol. 64, no. 88, pp. S84–S93, 2003. View at Google Scholar · View at Scopus
  12. E. García-López, B. Lindholm, and S. Davies, “An update on peritoneal dialysis solutions,” Nature Reviews Nephrology, vol. 8, no. 4, pp. 224–233, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Grassmann, S. Gioberge, S. Moeller, and G. Brown, “ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends,” Nephrology Dialysis Transplantation, vol. 20, no. 12, pp. 2587–2593, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. S. S. A. Fenton, D. E. Schaubel, M. Desmeules et al., “Hemodialysis versus peritoneal dialysis: a comparison of adjusted mortality rates,” American Journal of Kidney Diseases, vol. 30, no. 3, pp. 334–342, 1997. View at Google Scholar · View at Scopus
  15. A. J. Collins, W. Hao, H. Xia et al., “Mortality risks of peritoneal dialysis and hemodialysis,” American Journal of Kidney Diseases, vol. 34, no. 6, pp. 1065–1074, 1999. View at Google Scholar · View at Scopus
  16. D. E. Schaubel, H. I. Morrison, and S. S. A. Fenton, “Comparing mortality rates on CAPD/CCPD and hemodialysis. The Canadian experience: fact or fiction?” Peritoneal Dialysis International, vol. 18, no. 5, pp. 478–484, 1998. View at Google Scholar · View at Scopus
  17. E. F. Vonesh, J. J. Snyder, R. N. Foley, and A. J. Collins, “Mortality studies comparing peritoneal dialysis and hemodialysis: what do they tell us?” Kidney International, vol. 70, no. 103, pp. S3–S7, 2006. View at Google Scholar · View at Scopus
  18. R. Selgas, M.-J. Fernandez-Reyes, E. Bosque et al., “Functional longevity of the human peritoneum: how long is continuous peritoneal dialysis possible? Results of a prospective medium long-term study,” American Journal of Kidney Diseases, vol. 23, no. 1, pp. 64–73, 1994. View at Google Scholar · View at Scopus
  19. P. J. Margetts and P. Bonniaud, “Basic mechanisms and clinical implications of peritoneal fibrosis,” Peritoneal Dialysis International, vol. 23, no. 6, pp. 530–541, 2003. View at Google Scholar · View at Scopus
  20. J. Perl, S. J. Nessim, and J. M. Bargman, “The biocompatibility of neutral pH, low-GDP peritoneal dialysis solutions: benefit at bench, bedside, or both,” Kidney International, vol. 79, no. 8, pp. 814–824, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. J. D. Williams, K. J. Craig, N. Topley, and G. T. Williams, “Peritoneal dialysis: changes to the structure of the peritoneal membrane and potential for biocompatible solutions,” Kidney International, vol. 63, no. 84, pp. S158–S161, 2003. View at Google Scholar · View at Scopus
  22. J. D. Williams, N. Topley, K. J. Craig et al., “The euro-balance trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane,” Kidney International, vol. 66, no. 1, pp. 408–418, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Fischbach, A. Zaloszyc, B. Schaefer, and C. P. Schmitt, “Optimizing peritoneal dialysis prescription for volume control: the importance of varying dwell time and dwell volume,” Pediatric Nephrology, 2013. View at Publisher · View at Google Scholar
  24. C. P. Schmitt, A. Zaloszyc, B. Schaefer, and M. Fischbach, “Peritoneal dialysis tailored to pediatric needs,” International Journal of Nephrology, vol. 2011, Article ID 940267, 9 pages, 2011. View at Publisher · View at Google Scholar
  25. L. S. Aroeira, A. Aguilera, J. A. Sánchez-Tomero et al., “Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and potential therapeutic interventions,” Journal of the American Society of Nephrology, vol. 18, no. 7, pp. 2004–2013, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. G. T. González-Mateo, L. S. Aroeira, M. López-Cabrera, M. Ruiz-Ortega, A. Ortiz, and R. Selgas, “Pharmacological modulation of peritoneal injury induced by dialysis fluids: is it an option?” Nephrology Dialysis Transplantation, vol. 27, no. 2, pp. 478–481, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. H. F. H. Brulez and H. A. Verbrugh, “First-line defense mechanisms in the peritoneal cavity during peritoneal dialysis,” Peritoneal Dialysis International, vol. 15, no. 7, pp. S24–S34, 1995. View at Google Scholar · View at Scopus
  28. N. Di Paolo and G. Sacchi, “Atlas of peritoneal histology,” Peritoneal Dialysis International, vol. 20, supplement 3, pp. S5–S96, 2000. View at Google Scholar
  29. S. Combet, M.-L. Ferrier, M. Van Landschoot et al., “Chronic uremia induces permeability changes, increased nitric oxide synthase expression, and structural modifications in the peritoneum,” Journal of the American Society of Nephrology, vol. 12, no. 10, pp. 2146–2157, 2001. View at Google Scholar · View at Scopus
  30. J. D. Williams, K. J. Craig, N. Topley et al., “Morphologic changes in the peritoneal membrane of patients with renal disease,” Journal of the American Society of Nephrology, vol. 13, no. 2, pp. 470–479, 2002. View at Google Scholar · View at Scopus
  31. J. Plum, S. Hermann, A. Fusshöller et al., “Peritoneal sclerosis in peritoneal dialysis patients related to dialysis settings and peritoneal transport properties,” Kidney International, vol. 59, no. 78, pp. S42–S47, 2001. View at Google Scholar · View at Scopus
  32. J. A. Jiménez-Heffernan, A. Aguilera, L. S. Aroeira et al., “Immunohistochemical characterization of fibroblast subpopulations in normal peritoneal tissue and in peritoneal dialysis-induced fibrosis,” Virchows Archiv, vol. 444, no. 3, pp. 247–256, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. L. W. Morgan, A. Wieslander, M. Davies et al., “Glucose degradation products (GDP) retard remesothelialization independently of D-glucose concentration,” Kidney International, vol. 64, no. 5, pp. 1854–1866, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. M. A. M. Mateijsen, A. C. Van Der Wal, P. M. E. M. Hendriks et al., “Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis,” Peritoneal Dialysis International, vol. 19, no. 6, pp. 517–525, 1999. View at Google Scholar · View at Scopus
  35. R. T. Krediet, M. M. Zweers, A. C. van der Wal, and D. G. Struijk, “Neoangiogenesis in the peritoneal membrane,” Peritoneal Dialysis International, vol. 20, supplement 2, pp. S19–S25, 2000. View at Google Scholar · View at Scopus
  36. A. M. Sherif, M. Nakayama, Y. Maruyama et al., “Quantitative assessment of the peritoneal vessel density and vasculopathy in CAPD patients,” Nephrology Dialysis Transplantation, vol. 21, no. 6, pp. 1675–1681, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. P. J. Margetts and D. N. Churchill, “Acquired ultrafiltration dysfunction in peritoneal dialysis patients,” Journal of the American Society of Nephrology, vol. 13, no. 11, pp. 2787–2794, 2002. View at Google Scholar · View at Scopus
  38. R. T. Krediet, B. Lindholm, and B. Rippe, “Pathophysiology of peritoneal membrane failure,” Peritoneal Dialysis International, vol. 20, supplement 4, pp. S22–S42, 2000. View at Google Scholar · View at Scopus
  39. N. Topley, T. Liberek, A. Davenport, F.-K. Li, H. Fear, and J. D. Williams, “Activation of inflammation and leukocyte recruitment into the peritoneal cavity,” Kidney International, vol. 50, no. 56, pp. S17–S21, 1996. View at Google Scholar · View at Scopus
  40. K. N. Lai, S. C. Tang, and J. C. Leung, “Mediators of inflammation and fibrosis,” Peritoneal Dialysis International, vol. 27, supplement 2, pp. S65–S71, 2007. View at Google Scholar
  41. G. Baroni, A. Schuinski, T. P. de Moraes et al., “Inflammation and the peritoneal membrane: causes and impact on structure and function during peritoneal dialysis,” Mediators of Inflammation, vol. 2012, Article ID 912595, 4 pages, 2012. View at Publisher · View at Google Scholar
  42. N. Di Paolo and G. Garosi, “Peritoneal sclerosis,” Journal of Nephrology, vol. 12, no. 6, pp. 347–361, 1999. View at Google Scholar · View at Scopus
  43. G. Garosi, “Different aspects of peritoneal damage: fibrosis and sclerosis,” Contributions to Nephrology, vol. 163, pp. 45–53, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. A. M. Sherif, H. Yoshida, Y. Maruyama et al., “Comparison between the pathology of encapsulating sclerosis and simple sclerosis of the peritoneal membrane in chronic peritoneal dialysis,” Therapeutic Apheresis and Dialysis, vol. 12, no. 1, pp. 33–41, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. Y. Kawaguchi, H. Kawanishi, S. Mujais, N. Topley, and D. G. Oreopoulos, “Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment,” Peritoneal Dialysis International, vol. 20, no. 4, pp. S43–S55, 2000. View at Google Scholar · View at Scopus
  46. T. Augustine, P. W. Brown, S. D. Davies, A. M. Summers, and M. E. Wilkie, “Encapsulating peritoneal sclerosis: clinical significance and implications,” Nephron Clinical Practice, vol. 111, no. 2, pp. c149–c154, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. H. Kawanishi, Y. Kawaguchi, H. Fukui et al., “Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study,” American Journal of Kidney Diseases, vol. 44, no. 4, pp. 729–737, 2004. View at Publisher · View at Google Scholar · View at Scopus
  48. A. M. Summers, M. J. Clancy, F. Syed et al., “Single-center experience of encapsulating peritoneal sclerosis in patients on peritoneal dialysis for end-stage renal failure,” Kidney International, vol. 68, no. 5, pp. 2381–2388, 2005. View at Publisher · View at Google Scholar · View at Scopus
  49. M. W. J. A. Fieren, M. G. H. Betjes, M. R. Korte, and W. H. Boer, “Posttransplant encapsulating peritoneal sclerosis: a worrying new trend?” Peritoneal Dialysis International, vol. 27, no. 6, pp. 619–624, 2007. View at Google Scholar · View at Scopus
  50. N. Di Paolo, G. Sacchi, G. Garosi, P. Taganelli, and E. Gaggiotti, “Simple peritoneal sclerosis and sclerosing peritonitis: related or distinct entities?” International Journal of Artificial Organs, vol. 28, no. 2, pp. 117–128, 2005. View at Google Scholar · View at Scopus
  51. C. Goodlad and E. A. Brown, “Encapsulating peritoneal sclerosis: what have we learned?” Seminars in Nephrology, vol. 31, no. 2, pp. 183–198, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. J. Loureiro, G. Gonzalez-Mateo, J. Jimenez-Heffernan et al., “Are the mesothelial-to-mesenchymal transition, sclerotic peritonitis syndromes, and encapsulating peritoneal sclerosis part of the same process?” International Journal of Nephrology, vol. 2013, Article ID 263285, 7 pages, 2013. View at Publisher · View at Google Scholar
  53. N. Ferrara, H.-P. Gerber, and J. LeCouter, “The biology of VEGF and its receptors,” Nature Medicine, vol. 9, no. 6, pp. 669–676, 2003. View at Publisher · View at Google Scholar · View at Scopus
  54. R. Pecoits-Filho, M. R. T. Araújo, B. Lindholm et al., “Plasma and dialysate IL-6 and VEGF concentrations are associated with high peritoneal solute transport rate,” Nephrology Dialysis Transplantation, vol. 17, no. 8, pp. 1480–1486, 2002. View at Google Scholar · View at Scopus
  55. M. M. Zweers, D. R. De Waart, W. Smit, D. G. Struijk, and R. T. Krediet, “Growth factors VEGF and TGF-β1 in peritoneal dialysis,” Journal of Laboratory and Clinical Medicine, vol. 134, no. 2, pp. 124–132, 1999. View at Publisher · View at Google Scholar · View at Scopus
  56. M. M. Zweers, D. G. Struijk, W. Smit, and R. T. Krediet, “Vascular endothelial growth factor in peritoneal dialysis: a longitudinal follow-up,” Journal of Laboratory and Clinical Medicine, vol. 137, no. 2, pp. 125–132, 2001. View at Publisher · View at Google Scholar · View at Scopus
  57. L. S. Aroeira, A. Aguilera, R. Selgas et al., “Mesenchymal conversion of mesothelial cells as a mechanism responsible for high solute transport rate in peritoneal dialysis: role of vascular endothelial growth factor,” American Journal of Kidney Diseases, vol. 46, no. 5, pp. 938–948, 2005. View at Publisher · View at Google Scholar · View at Scopus
  58. A. Aguilera, M. Yáñez-Mo, R. Selgas, F. Sánchez-Madrid, and M. López-Cabrera, “Epithelial to mesenchymal transition as a triggering factor of peritoneal membrane fibrosis and angiogenesis in peritoneal dialysis patients,” Current Opinion in Investigational Drugs, vol. 6, no. 3, pp. 262–268, 2005. View at Google Scholar · View at Scopus
  59. S. Mandl-Weber, C. D. Cohen, B. Haslinger, M. Kretzler, and T. Sitter, “Vascular endothelial growth factor production and regulation in human peritoneal mesothelial cells,” Kidney International, vol. 61, no. 2, pp. 570–578, 2002. View at Publisher · View at Google Scholar · View at Scopus
  60. H. Ha, M. K. Cha, H. N. Choi, and H. B. Lee, “Effects of peritoneal dialysis solutions on the secretion of growth factors and extracellular matrix proteins by human peritoneal mesothelial cells,” Peritoneal Dialysis International, vol. 22, no. 2, pp. 171–177, 2002. View at Google Scholar · View at Scopus
  61. R. Catar, J. Witowski, P. Wagner et al., “The proto-oncogene c-Fos transcriptionally regulates VEGF production during peritoneal inflammation,” Kidney International, vol. 84, pp. 1119–1128, 2013. View at Publisher · View at Google Scholar
  62. M. L. Perez-Lozano, P. Sandoval, A. Rynne-Vidal et al., “Functional relevance of the switch of VEGF receptors/co-receptors during peritoneal dialysis-induced mesothelial to mesenchymal transition,” PLoS ONE, vol. 8, no. 4, Article ID e60776, 2013. View at Google Scholar
  63. R. Selgas, A. Bajo, J. A. Jiménez-Heffernan et al., “Epithelial-to-mesenchymal transition of the mesothelial cell: its role in the response of the peritoneum to dialysis,” Nephrology Dialysis Transplantation, vol. 21, supplement 2, pp. ii2–ii7, 2006. View at Publisher · View at Google Scholar · View at Scopus
  64. J. A. Jiménez-Heffernan, C. Perna, M. A. Bajo et al., “Tissue distribution of hyalinazing vasculopathy lesions in peritoneal dialysis patients. An autopsy study,” Pathology Research and Practice, vol. 204, no. 8, pp. 563–567, 2008. View at Publisher · View at Google Scholar · View at Scopus
  65. G. Del Peso, J. A. Jiménez-Heffernan, M. A. Bajo et al., “Epithelial-to-mesenchymal transition of mesothelial cells is an early event during peritoneal dialysis and is associated with high peritoneal transport,” Kidney International, vol. 73, no. 108, pp. S26–S33, 2008. View at Publisher · View at Google Scholar · View at Scopus
  66. P. J. Margetts, S. Gyorffy, M. Kolb et al., “Antiangiogenic and antifibrotic gene therapy in a chronic infusion model of peritoneal dialysis in rats,” Journal of the American Society of Nephrology, vol. 13, no. 3, pp. 721–728, 2002. View at Google Scholar · View at Scopus
  67. P. J. Margetts, M. Kolb, L. Yu et al., “Inflammatory cytokines, angiogenesis, and fibrosis in the rat peritoneum,” The American Journal of Pathology, vol. 160, no. 6, pp. 2285–2294, 2002. View at Google Scholar · View at Scopus
  68. D. Cina, P. Patel, J. C. Bethune et al., “Peritoneal morphological and functional changes associated with platelet-derived growth factor B,” Nephrology Dialysis Transplantation, vol. 24, no. 2, pp. 448–457, 2009. View at Publisher · View at Google Scholar · View at Scopus
  69. Y. Sekiguchi, J. Zhang, S. Patterson et al., “Rapamycin inhibits transforming growth factor beta-induced peritoneal angiogenesis by blocking the secondary hypoxic response,” Journal of Cellular and Molecular Medicine, vol. 16, no. 8, pp. 1934–1945, 2012. View at Google Scholar
  70. G. Gabbiani, B. J. Hirschel, G. B. Ryan, P. R. Statkov, and G. Majno, “Granulation tissue as a contractile organ. A study of structure and function,” Journal of Experimental Medicine, vol. 135, no. 4, pp. 719–734, 1972. View at Google Scholar · View at Scopus
  71. W. Schürch, T. A. Seemayer, and G. Gabbiani, “The myofibroblast: a quarter century after its discovery,” The American Journal of Surgical Pathology, vol. 22, no. 2, pp. 141–147, 1998. View at Google Scholar · View at Scopus
  72. D. W. Powell, R. C. Mifflin, J. D. Valentich, S. E. Crowe, J. I. Saada, and A. B. West, “Myofibroblasts. I. Paracrine cells important in health and disease,” The American Journal of Physiology: Cell Physiology, vol. 277, no. 1, part 1, pp. C1–C19, 1999. View at Google Scholar · View at Scopus
  73. S. H. Phan, “Fibroblast phenotypes in pulmonary fibrosis,” American Journal of Respiratory Cell and Molecular Biology, vol. 29, no. 3, pp. S87–S92, 2003. View at Google Scholar · View at Scopus
  74. G. Del Peso, J. A. Jiménez-Heffernan, M. A. Bajo et al., “Myofibroblastic differentiation in simple peritoneal sclerosis,” International Journal of Artificial Organs, vol. 28, no. 2, pp. 135–140, 2005. View at Google Scholar · View at Scopus
  75. S. V. Bertoli, L. Buzzi, D. Ciurlino, M. Maccario, and S. Martino, “Morpho-functional study of peritoneum in peritoneal dialysis patients,” Journal of Nephrology, vol. 16, no. 3, pp. 373–378, 2003. View at Google Scholar · View at Scopus
  76. V. S. LeBleu, G. Taduri, J. O'Connell et al., “Origin and function of myofibroblasts in kidney fibrosis,” Nature Medicine, vol. 19, no. 8, pp. 1047–1053, 2013. View at Publisher · View at Google Scholar
  77. B. D. Humphreys, S.-L. Lin, A. Kobayashi et al., “Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis,” The American Journal of Pathology, vol. 176, no. 1, pp. 85–97, 2010. View at Publisher · View at Google Scholar · View at Scopus
  78. M. Zeisberg and J. S. Duffield, “Resolved: EMT produces fibroblasts in the kidney,” Journal of the American Society of Nephrology, vol. 21, no. 8, pp. 1247–1253, 2010. View at Publisher · View at Google Scholar · View at Scopus
  79. S. E. Quaggin and A. Kapus, “Scar wars: mapping the fate of epithelial-mesenchymal-myofibroblast transition,” Kidney International, vol. 80, no. 1, pp. 41–50, 2011. View at Publisher · View at Google Scholar · View at Scopus
  80. M. Fragiadaki and R. M. Mason, “Epithelial-mesenchymal transition in renal fibrosis—evidence for and against,” International Journal of Experimental Pathology, vol. 92, no. 3, pp. 143–150, 2011. View at Publisher · View at Google Scholar · View at Scopus
  81. W. Kriz, B. Kaissling, and M. Le Hir, “Epithelial-mesenchymal transition (EMT) in kidney fibrosis: fact or fantasy?” Journal of Clinical Investigation, vol. 121, no. 2, pp. 468–474, 2011. View at Publisher · View at Google Scholar · View at Scopus
  82. J. Loureiro, A. Aguilera, R. Selgas et al., “Blocking TGF-β1 protects the peritoneal membrane from dialysate-induced damage,” Journal of the American Society of Nephrology, vol. 22, no. 9, pp. 1682–1695, 2011. View at Publisher · View at Google Scholar · View at Scopus
  83. K. Iwaisako, D. A. Brenner, and T. Kisseleva, “What's new in liver fibrosis? The origin of myofibroblasts in liver fibrosis,” Journal of Gastroenterology and Hepatology, vol. 27, supplement s2, pp. 65–68, 2012. View at Publisher · View at Google Scholar · View at Scopus
  84. A. J. Gilbane, C. P. Denton, and A. M. Holmes, “Scleroderma pathogenesis: a pivotal role for fibroblasts as effector cells,” Arthritis Research & Therapy, vol. 15, no. 3, article 215, 2013. View at Publisher · View at Google Scholar
  85. K. T. Weber, Y. Sun, S. K. Bhattacharya et al., “Myofibroblast-mediated mechanisms of pathological remodelling of the heart,” Nature Reviews Cardiology, vol. 10, no. 1, pp. 15–26, 2013. View at Publisher · View at Google Scholar
  86. M. T. Grande and J. M. López-Novoa, “Fibroblast activation and myofibroblast generation in obstructive nephropathy,” Nature Reviews Nephrology, vol. 5, no. 6, pp. 319–328, 2009. View at Publisher · View at Google Scholar · View at Scopus
  87. R. Bucala, L. A. Spiegel, J. Chesney, M. Hogan, and A. Cerami, “Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair,” Molecular Medicine, vol. 1, no. 1, pp. 71–81, 1994. View at Google Scholar · View at Scopus
  88. N. Sakai, T. Wada, H. Yokoyama et al., “Secondary lymphoid tissue chemokine (SLC/CCL21)/CCR7 signaling regulates fibrocytes in renal fibrosis,” Proceedings of the National Academy of Sciences of the USA, vol. 103, no. 38, pp. 14098–14103, 2006. View at Publisher · View at Google Scholar · View at Scopus
  89. A. Bellini and S. Mattoli, “The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses,” Laboratory Investigation, vol. 87, no. 9, pp. 858–870, 2007. View at Publisher · View at Google Scholar · View at Scopus
  90. M. Iwano, D. Plieth, T. M. Danoff, C. Xue, H. Okada, and E. G. Neilson, “Evidence that fibroblasts derive from epithelium during tissue fibrosis,” Journal of Clinical Investigation, vol. 110, no. 3, pp. 341–350, 2002. View at Publisher · View at Google Scholar · View at Scopus
  91. J. S. Zolak, R. Jagirdar, R. Surolia et al., “Pleural mesothelial cell differentiation and invasion in fibrogenic lung injury,” The American Journal of Pathology, vol. 182, no. 4, pp. 1239–1247, 2013. View at Publisher · View at Google Scholar
  92. M. Guarino, A. Tosoni, and M. Nebuloni, “Direct contribution of epithelium to organ fibrosis: epithelial-mesenchymal transition,” Human Pathology, vol. 40, no. 10, pp. 1365–1376, 2009. View at Publisher · View at Google Scholar · View at Scopus
  93. E. M. Zeisberg, S. E. Potenta, H. Sugimoto, M. Zeisberg, and R. Kalluri, “Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition,” Journal of the American Society of Nephrology, vol. 19, no. 12, pp. 2282–2287, 2008. View at Publisher · View at Google Scholar · View at Scopus
  94. J. Li, X. Qu, and J. F. Bertram, “Endothelial-myofibroblast transition contributes to the early development of diabetic renal interstitial fibrosis in streptozotocin-induced diabetic mice,” The American Journal of Pathology, vol. 175, no. 4, pp. 1380–1388, 2009. View at Publisher · View at Google Scholar · View at Scopus
  95. E. M. Zeisberg, O. Tarnavski, M. Zeisberg et al., “Endothelial-to-mesenchymal transition contributes to cardiac fibrosis,” Nature Medicine, vol. 13, no. 8, pp. 952–961, 2007. View at Publisher · View at Google Scholar · View at Scopus
  96. S.-L. Lin, T. Kisseleva, D. A. Brenner, and J. S. Duffield, “Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney,” The American Journal of Pathology, vol. 173, no. 6, pp. 1617–1627, 2008. View at Publisher · View at Google Scholar · View at Scopus
  97. M. Yáñez-Mó, E. Lara-Pezzi, R. Selgas et al., “Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells,” The New England Journal of Medicine, vol. 348, no. 5, pp. 403–413, 2003. View at Publisher · View at Google Scholar · View at Scopus
  98. S. E. Mutsaers, “Mesothelial cells: their structure, function and role in serosal repair,” Respirology, vol. 7, no. 3, pp. 171–191, 2002. View at Publisher · View at Google Scholar · View at Scopus
  99. S. E. Mutsaers, “The mesothelial cell,” International Journal of Biochemistry and Cell Biology, vol. 36, no. 1, pp. 9–16, 2004. View at Publisher · View at Google Scholar · View at Scopus
  100. S. Yung and T. M. Chan, “Glycosaminoglycans and proteoglycans: overlooked entities?” Peritoneal Dialysis International, vol. 27, supplement 2, pp. S104–S109, 2007. View at Google Scholar · View at Scopus
  101. A. H. Yang, J. Y. Chen, and J. K. Lin, “Myofibroblastic conversion of mesothelial cells,” Kidney International, vol. 63, no. 4, pp. 1530–1539, 2003. View at Publisher · View at Google Scholar · View at Scopus
  102. M. López-Cabrera, A. Aguilera, L. S. Aroeira et al., “Ex vivo analysis of dialysis effluent-derived mesothelial cells as an approach to unveiling the mechanism of peritoneal membrane failure,” Peritoneal Dialysis International, vol. 26, no. 1, pp. 26–34, 2006. View at Google Scholar · View at Scopus
  103. M. A. Bajo, G. del Peso, M. A. Castro et al., “Pathogenic significance of hypertrophic mesothelial cells in peritoneal effluent and ex vivo culture,” Advances in Peritoneal Dialysis, vol. 20, pp. 43–46, 2004. View at Google Scholar · View at Scopus
  104. K. Ksi̧zek, K. Korybalska, A. Jörres, and J. Witowski, “Accelerated senescence of human peritoneal mesothelial cells exposed to high glucose: the role of TGF-β1,” Laboratory Investigation, vol. 87, no. 4, pp. 345–356, 2007. View at Publisher · View at Google Scholar · View at Scopus
  105. R. Strippoli, I. Benedicto, M. L. Perez Lozano et al., “Inhibition of transforming growth factor-activated kinase 1 (TAK1) blocks and reverses epithelial to mesenchymal transition of mesothelial cells,” PLoS ONE, vol. 7, no. 2, Article ID e31492, 2012. View at Publisher · View at Google Scholar · View at Scopus
  106. P. Patel, Y. Sekiguchi, K.-H. Oh, S. E. Patterson, M. R. J. Kolb, and P. J. Margetts, “Smad3-dependent and-independent pathways are involved in peritoneal membrane injury,” Kidney International, vol. 77, no. 4, pp. 319–328, 2010. View at Publisher · View at Google Scholar · View at Scopus
  107. P. J. Margetts, P. Bonniaud, L. Liu et al., “Transient overexpression of TGF-β1 induces epithelial mesenchymal transition in the rodent peritoneum,” Journal of the American Society of Nephrology, vol. 16, no. 2, pp. 425–436, 2005. View at Publisher · View at Google Scholar · View at Scopus
  108. P. Sandoval, J. Loureiro, G. González-Mateo et al., “PPAR-γ agonist rosiglitazone protects peritoneal membrane from dialysis fluid-induced damage,” Laboratory Investigation, vol. 90, no. 10, pp. 1517–1532, 2010. View at Publisher · View at Google Scholar · View at Scopus
  109. K. K. Mubarak, A. Montes-Worboys, D. Regev et al., “Parenchymal trafficking of pleural mesothelial cells in idiopathic pulmonary fibrosis,” European Respiratory Journal, vol. 39, no. 1, pp. 133–140, 2012. View at Publisher · View at Google Scholar · View at Scopus
  110. Y. Li, J. Wang, and K. Asahina, “Mesothelial cells give rise to hepatic stellate cells and myofibroblasts via mesothelial-mesenchymal transition in liver injury,” Proceedings of the National Academy of Sciences of the USA, vol. 110, no. 6, pp. 2324–2329, 2013. View at Publisher · View at Google Scholar
  111. J. Loureiro, P. Sandoval, G. del Peso et al., “Tamoxifen ameliorates peritoneal membrane damage by blocking mesothelial to mesenchymal transition in peritoneal dialysis,” PLoS ONE, vol. 8, no. 4, Article ID e61165, 2013. View at Google Scholar
  112. R. Strippoli, I. Benedicto, M. L. P. Lozano, A. Cerezo, M. López-Cabrera, and M. A. del Pozo, “Epithelial-to-mesenchymal transition of peritoneal mesothelial cells is regulated by an ERK/NF-κB/Snail1 pathway,” Disease Models and Mechanisms, vol. 1, no. 4-5, pp. 264–274, 2008. View at Publisher · View at Google Scholar · View at Scopus
  113. F. Zhu, T. Li, F. Qiu et al., “Preventive effect of Notch signaling inhibition by a γ-secretase inhibitor on peritoneal dialysis fluid-induced peritoneal fibrosis in rats,” The American Journal of Pathology, vol. 176, no. 2, pp. 650–659, 2010. View at Publisher · View at Google Scholar · View at Scopus
  114. R. Vargha, M. Endemann, K. Kratochwill et al., “Ex vivo reversal of in vivo transdifferentiation in mesothelial cells grown from peritoneal dialysate effluents,” Nephrology Dialysis Transplantation, vol. 21, no. 10, pp. 2943–2947, 2006. View at Publisher · View at Google Scholar · View at Scopus
  115. M.-A. Yu, K.-S. Shin, J. H. Kim et al., “HGF and BMP-7 ameliorate high glucose-induced epithelial-to-mesenchymal transition of peritoneal mesothelium,” Journal of the American Society of Nephrology, vol. 20, no. 3, pp. 567–581, 2009. View at Publisher · View at Google Scholar · View at Scopus
  116. J. Loureiro, M. Schilte, A. Aguilera et al., “BMP-7 blocks mesenchymal conversion of mesothelial cells and prevents peritoneal damage induced by dialysis fluid exposure,” Nephrology Dialysis Transplantation, vol. 25, no. 4, pp. 1098–1108, 2010. View at Publisher · View at Google Scholar · View at Scopus
  117. X. Wang, X. Li, L. Ye et al., “Smad7 inhibits TGF-beta1-induced MCP-1 upregulation through a MAPK/p38 pathway in rat peritoneal mesothelial cells,” International Urology and Nephrology, vol. 45, no. 3, pp. 899–907, 2013. View at Publisher · View at Google Scholar
  118. H. Guo, J. C. K. Leung, F. L. Man et al., “Smad7 transgene attenuates peritoneal fibrosis in uremic rats treated with peritoneal dialysis,” Journal of the American Society of Nephrology, vol. 18, no. 10, pp. 2689–2703, 2007. View at Publisher · View at Google Scholar · View at Scopus
  119. J. Nie, X. Dou, W. Hao et al., “Smad7 gene transfer inhibits peritoneal fibrosis,” Kidney International, vol. 72, no. 11, pp. 1336–1344, 2007. View at Publisher · View at Google Scholar · View at Scopus
  120. R. Strippoli, I. Benedicto, M. Foronda et al., “p38 maintains E-cadherin expression by modulating TAK1-NF-κB during epithelial-to-mesenchymal transition,” Journal of Cell Science, vol. 123, no. 24, pp. 4321–4331, 2010. View at Publisher · View at Google Scholar · View at Scopus
  121. Z. Li, P. J. Wermuth, B. S. Benn et al., “Caveolin-1 deficiency induces spontaneous endothelial-to-mesenchymal transition in murine pulmonary endothelial cells in vitro,” The American Journal of Pathology, vol. 182, no. 2, pp. 325–331, 2013. View at Publisher · View at Google Scholar
  122. K. N. Lai, K. B. Lai, C. W. K. Lam, T. M. Chan, F. K. Li, and J. C. K. Leung, “Changes of cytokine profiles during peritonitis in patients on continuous ambulatory peritoneal dialysis,” American Journal of Kidney Diseases, vol. 35, no. 4, pp. 644–652, 2000. View at Google Scholar · View at Scopus
  123. A. S. Gangji, K. S. Brimble, and P. J. Margetts, “Association between markers of inflammation, fibrosis and hypervolemia in peritoneal dialysis patients,” Blood Purification, vol. 28, no. 4, pp. 354–358, 2009. View at Publisher · View at Google Scholar · View at Scopus
  124. Q. Yao, K. Pawlaczyk, E. R. Ayala et al., “The role of the TGF/Smad signaling pathway in peritoneal fibrosis induced by peritoneal dialysis solutions,” Nephron Experimental Nephrology, vol. 109, no. 2, pp. e71–e78, 2008. View at Publisher · View at Google Scholar · View at Scopus
  125. P. J. Margetts, M. Kolb, T. Galt, C. M. Hoff, T. R. Shockley, and J. Gauldie, “Gene transfer of transforming growth factor-β1 to the rat peritoneum: effects on membrane function,” Journal of the American Society of Nephrology, vol. 12, no. 10, pp. 2029–2039, 2001. View at Google Scholar · View at Scopus
  126. J. Xu, S. Lamouille, and R. Derynck, “TGF-Β-induced epithelial to mesenchymal transition,” Cell Research, vol. 19, no. 2, pp. 156–172, 2009. View at Publisher · View at Google Scholar · View at Scopus
  127. T. Gui, Y. Sun, A. Shimokado, and Y. Muragaki, “The roles of mitogen-activated protein kinase pathways in TGF-β-induced epithelial-mesenchymal transition,” Journal of Signal Transduction, vol. 2012, Article ID 289243, 10 pages, 2012. View at Publisher · View at Google Scholar
  128. Y. Liu, “New insights into epithelial-mesenchymal transition in kidney fibrosis,” Journal of the American Society of Nephrology, vol. 21, no. 2, pp. 212–222, 2010. View at Publisher · View at Google Scholar · View at Scopus
  129. Y. Shi and J. Massagué, “Mechanisms of TGF-β signaling from cell membrane to the nucleus,” Cell, vol. 113, no. 6, pp. 685–700, 2003. View at Publisher · View at Google Scholar · View at Scopus
  130. R. Weiskirchen and S. K. Meurer, “BMP-7 counteracting TGF-beta1 activities in organ fibrosis,” Frontiers in Bioscience, vol. 18, pp. 1407–1434, 2013. View at Publisher · View at Google Scholar
  131. P. Boor, T. Ostendorf, and J. Floege, “Renal fibrosis: novel insights into mechanisms and therapeutic targets,” Nature Reviews Nephrology, vol. 6, no. 11, pp. 643–656, 2010. View at Publisher · View at Google Scholar · View at Scopus
  132. C. Dai and Y. Liu, “Hepatocyte growth factor antagonizes the profibrotic action of TGF-β1 in mesangial cells by stabilizing Smad transcriptional corepressor TGIF,” Journal of the American Society of Nephrology, vol. 15, no. 6, pp. 1402–1412, 2004. View at Publisher · View at Google Scholar · View at Scopus
  133. J. Yang, C. Dai, and Y. Liu, “A novel mechanism by which hepatocyte growth factor blocks tubular epithelial to mesenchymal transition,” Journal of the American Society of Nephrology, vol. 16, no. 1, pp. 68–78, 2005. View at Publisher · View at Google Scholar · View at Scopus
  134. R. Tan, X. Zhang, J. Yang, Y. Li, and Y. Liu, “Molecular basis for the cell type-specific induction of SnoN expression by hepatocyte growth factor,” Journal of the American Society of Nephrology, vol. 18, no. 8, pp. 2340–2349, 2007. View at Publisher · View at Google Scholar · View at Scopus
  135. J. C. K. Leung, L. Y. Y. Chan, K. Y. Tam et al., “Regulation of CCN2/CTGF and related cytokines in cultured peritoneal cells under conditions simulating peritoneal dialysis,” Nephrology Dialysis Transplantation, vol. 24, no. 2, pp. 458–469, 2009. View at Publisher · View at Google Scholar · View at Scopus
  136. K. H. Zarrinkalam, J. M. Stanley, J. Gray, N. Oliver, and R. J. Faull, “Connective tissue growth factor and its regulation in the peritoneal cavity of peritoneal dialysis patients,” Kidney International, vol. 64, no. 1, pp. 331–338, 2003. View at Publisher · View at Google Scholar · View at Scopus
  137. C.-C. Szeto, K.-B. Lai, K.-M. Chow, C. Y.-K. Szeto, T. Y.-H. Wong, and P. K.-T. Li, “Differential effects of transforming growth factor-beta on the synthesis of connective tissue growth factor and vascular endothelial growth factor by peritoneal mesothelial cell,” Nephron Experimental Nephrology, vol. 99, no. 4, pp. e95–e104, 2005. View at Google Scholar · View at Scopus
  138. M. Mizutani, Y. Ito, M. Mizuno et al., “Connective tissue growth factor (CTGF/CCN2) is increased in peritoneal dialysis patients with high peritoneal solute transport rate,” The American Journal of Physiology: Renal Physiology, vol. 298, no. 3, pp. F721–F733, 2010. View at Publisher · View at Google Scholar · View at Scopus
  139. J. G. Abreu, N. I. Ketpura, B. Reversade, and E. M. De Robertis, “Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-β,” Nature Cell Biology, vol. 4, no. 8, pp. 599–604, 2002. View at Publisher · View at Google Scholar · View at Scopus
  140. T. Q. Nguyen, P. Roestenberg, F. A. Van Nieuwenhoven et al., “CTGF inhibits BMP-7 signaling in diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 19, no. 11, pp. 2098–2107, 2008. View at Publisher · View at Google Scholar · View at Scopus
  141. M. Zeisberg, “Bone morphogenic protein-7 and the kidney: current concepts and open questions,” Nephrology Dialysis Transplantation, vol. 21, no. 3, pp. 568–573, 2006. View at Publisher · View at Google Scholar · View at Scopus
  142. J. Massague, “How cells read TGF-beta signals,” Nature Reviews Molecular Cell Biology, vol. 1, no. 3, pp. 169–178, 2000. View at Publisher · View at Google Scholar
  143. R. Derynck and Y. E. Zhang, “Smad-dependent and Smad-independent pathways in TGF-β family signalling,” Nature, vol. 425, no. 6958, pp. 577–584, 2003. View at Publisher · View at Google Scholar · View at Scopus
  144. B. W. Doble and J. R. Woodgett, “Role of glycogen synthase kinase-3 in cell fate and epithelial-mesenchymal transitions,” Cells Tissues Organs, vol. 185, no. 1–3, pp. 73–84, 2007. View at Publisher · View at Google Scholar · View at Scopus
  145. J. P. Thiery and J. P. Sleeman, “Complex networks orchestrate epithelial-mesenchymal transitions,” Nature Reviews Molecular Cell Biology, vol. 7, no. 2, pp. 131–142, 2006. View at Publisher · View at Google Scholar · View at Scopus
  146. R. E. Bachelder, S.-O. Yoon, C. Franci, A. García De Herreros, and A. M. Mercurio, “Glycogen synthase kinase-3 is an endogenous inhibitor of Snail transcription: Implications for the epithelial—mesenchymal transition,” Journal of Cell Biology, vol. 168, no. 1, pp. 29–33, 2005. View at Publisher · View at Google Scholar · View at Scopus
  147. B. P. Zhou, J. Deng, W. Xia et al., “Dual regulation of Snail by GSK-3β-mediated phosphorylation in control of epithelial-mesenchymal transition,” Nature Cell Biology, vol. 6, no. 10, pp. 931–940, 2004. View at Publisher · View at Google Scholar · View at Scopus
  148. L. S. Aroeira, E. Lara-Pezzi, J. Loureiro et al., “Cyclooxygenase-2 mediates dialysate-Lnduced alterations of the peritoneal membrane,” Journal of the American Society of Nephrology, vol. 20, no. 3, pp. 582–592, 2009. View at Publisher · View at Google Scholar · View at Scopus
  149. P. Fabbrini, M. N. Schilte, M. Zareie et al., “Celecoxib treatment reduces peritoneal fibrosis and angiogenesis and prevents ultrafiltration failure in experimental peritoneal dialysis,” Nephrology Dialysis Transplantation, vol. 24, no. 12, pp. 3669–3676, 2009. View at Publisher · View at Google Scholar · View at Scopus
  150. M. A. Bajo, M. L. Príez-Lozano, P. Albar-Vizcaino et al., “Low-GDP peritoneal dialysis fluid (“balance”) has less impact in vitro and ex vivo on epithelial-to-mesenchymal transition (EMT) of mesothelial cells than a standard fluid,” Nephrology Dialysis Transplantation, vol. 26, no. 1, pp. 282–291, 2011. View at Publisher · View at Google Scholar · View at Scopus
  151. A. Fernandez-Perpen, M. L. Perez-Lozano, M. A. Bajo et al., “Influence of bicarbonate/low-GDP peritoneal dialysis fluid (BicaVera) on in vitro and ex vivo epithelial-to-mesenchymal transition of mesothelial cells,” Peritoneal Dialysis International, vol. 32, no. 3, pp. 292–304, 2012. View at Publisher · View at Google Scholar
  152. A. Yoshimura, Y. Wakabayashi, and T. Mori, “Cellular and molecular basis for the regulation of inflammation by TGF-β,” Journal of Biochemistry, vol. 147, no. 6, pp. 781–792, 2010. View at Publisher · View at Google Scholar · View at Scopus
  153. X. Wang, J. Nie, Z. Jia et al., “Impaired TGF-β signalling enhances peritoneal inflammation induced by E. Coli in rats,” Nephrology Dialysis Transplantation, vol. 25, no. 2, pp. 399–412, 2010. View at Publisher · View at Google Scholar · View at Scopus
  154. T. Matsuoka, Y. Maeda, K. Matsuo et al., “Hepatocyte growth factor prevents peritoneal fibrosis in an animal model of encapsulating peritoneal sclerosis,” Journal of Nephrology, vol. 21, no. 1, pp. 64–73, 2008. View at Google Scholar · View at Scopus
  155. G. E. Friedlaender, C. R. Perry, J. D. Cole et al., “Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions,” The Journal of Bone and Joint Surgery A, vol. 83, supplement 1, part 2, pp. S151–S158, 2001. View at Google Scholar · View at Scopus
  156. H. Sugimoto, V. S. LeBleu, D. Bosukonda et al., “Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis,” Nature Medicine, vol. 18, no. 3, pp. 396–404, 2012. View at Publisher · View at Google Scholar · View at Scopus
  157. R. B. Clark, D. Bishop-Bailey, T. Estrada-Hernandez, T. Hla, L. Puddington, and S. J. Padula, “The nuclear receptor PPARγ and immunoregulation: PPARγ mediates inhibition of helper T cell responses,” Journal of Immunology, vol. 164, no. 3, pp. 1364–1371, 2000. View at Google Scholar · View at Scopus
  158. M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, “The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation,” Nature, vol. 391, no. 6662, pp. 79–82, 1998. View at Publisher · View at Google Scholar · View at Scopus
  159. S. J. Nessim, J. Perl, and J. M. Bargman, “The renin-angiotensin-aldosterone system in peritoneal dialysis: is what is good for the kidney also good for the peritoneum,” Kidney International, vol. 78, no. 1, pp. 23–28, 2010. View at Publisher · View at Google Scholar · View at Scopus
  160. J. Perez-Martinez, F. C. Perez-Martinez, B. Carrion et al., “Aliskiren prevents the toxic effects of peritoneal dialysis fluids during chronic dialysis in rats,” PLoS ONE, vol. 7, no. 4, Article ID e36268, 2012. View at Google Scholar
  161. G. Koçak, A. Azak, H. M. Astarci et al., “Effects of renin-angiotensin-aldosterone system blockade on chlorhexidine gluconate-induced sclerosing encapsulated peritonitis in rats,” Therapeutic Apheresis and Dialysis, vol. 16, no. 1, pp. 75–80, 2012. View at Publisher · View at Google Scholar · View at Scopus
  162. S. Duman, K. Wieczorowska-Tobis, A. Styszynski, B. Kwiatkowska, A. Breborowicz, and D. G. Oreopoulos, “Intraperitoneal enalapril ameliorates morphologic changes induced by hypertonic peritoneal dialysis solutions in rat peritoneum,” Advances in Peritoneal Dialysis, vol. 20, pp. 31–36, 2004. View at Google Scholar · View at Scopus
  163. J. Rojas-Rivera, C. de la Piedra, A. Ramos, A. Ortiz, and J. Egido, “The expanding spectrum of biological actions of vitamin D,” Nephrology Dialysis Transplantation, vol. 25, no. 9, pp. 2850–2865, 2010. View at Publisher · View at Google Scholar · View at Scopus